Trial Profile

A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemias or Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idasanutlin (Primary) ; Cyclophosphamide; Cytarabine; Fludarabine; Hydrocortisone; Methotrexate; Topotecan; Venetoclax
Indications Acute myeloid leukaemia; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Roche

26 Nov 2024 Status changed from completed to discontinued.
03 Jul 2024 Status changed from active, no longer recruiting to completed.
27 Jun 2024 Planned primary completion date changed from 30 Dec 2025 to 30 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com